Novo Nordisk seeks injunction to halt Eli Lilly's obesity drug ads

Novo Nordisk filed a motion in a New Jersey federal court asking for a preliminary injunction that would stop Eli Lilly's advertisements for its obesity treatments.

Novo claims the ads are misleading, suggesting Lilly's GLP‑1 drugs are broadly superior to Novo's products, diverting patients to Zepbound and Mounjaro and creating false impressions about Wegovy and Ozempic, which it says erodes goodwill built over decades.

Lilly denied the allegations, stating its campaign is truthful. Novo's lawyers argue that each day the ads run causes damage that monetary compensation cannot undo.